Ozempic Legal & Patent Challenges: FDA Approval, Label History, and Safety Litigation

How and When Ozempic Got FDA Approval

The FDA approved Ozempic on December 5, 2017 under NDA 209637, making semaglutide the first once-weekly GLP-1 receptor agonist with cardiovascular outcome data built directly into the original label. The approval was based on the six-trial SUSTAIN program, which collectively enrolled more than 8,000 adults with type 2 diabetes across a range of background therapies.

The SUSTAIN Trial Program

The key efficacy evidence came from SUSTAIN-1 through SUSTAIN-6. SUSTAIN-7 (N=1,201), published in 2018, provided a head-to-head comparison showing semaglutide 1.0 mg reduced HbA1c by 1.9 percentage points versus dulaglutide 1.5 mg's 1.4 percentage points at 40 weeks (P<0.001) [1]. That difference influenced prescriber uptake well before any patent dispute arose.

SUSTAIN-6, the cardiovascular outcomes trial (N=3,297, median 2.1 years), showed a 26% relative risk reduction in major adverse cardiovascular events (MACE) with semaglutide versus placebo [2]. The FDA used that data to approve a cardiovascular risk reduction claim in 2020, requiring a label update discussed below.

The Original Label Language

The 2017 label carried a black-box warning for thyroid C-cell tumors, grounded in rodent carcinogenicity data. No human cases of medullary thyroid carcinoma (MTC) attributable to semaglutide had been confirmed at approval, but the agency required contraindication language for patients with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2). That language remains unchanged through the current 2024 label revision.

Ozempic Label Changes Since 2017

The Ozempic prescribing information has been updated at least three times since initial approval, each time driven by new safety or efficacy data from post-market sources.

2020 Cardiovascular Outcomes Update

Following the FDA's formal review of SUSTAIN-6 outcomes, the label was revised in 2020 to include the statement: "Ozempic is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease." [3] This language mirrors wording in the FDA-approved labeling document accessible via Drugs@FDA for NDA 209637.

2022 Gastroparesis and GI Warning Expansion

Post-market adverse event reports submitted to FDA MedWatch flagged a cluster of delayed gastric emptying cases severe enough to require hospitalization. The 2022 label update added explicit language noting that semaglutide "has not been studied in patients with severe gastroparesis" and warning prescribers about the risk in patients with pre-existing gastrointestinal motility disorders [4]. The American Neurogastroenterology and Motility Society estimated in a 2023 position statement that GLP-1 receptor agonist-related gastroparesis hospitalizations rose roughly 33% year-over-year between 2021 and 2023, though causality remains under investigation.

2024 Suicidality Signal Review

In 2023, the European Medicines Agency (EMA) and the FDA initiated parallel reviews of a potential suicidality or self-harm signal associated with GLP-1 receptor agonists, following spontaneous adverse event reports. By early 2024, both agencies concluded that the available data did not establish a causal relationship between semaglutide and suicidal ideation. The FDA did not add a suicidality warning to the Ozempic label, but it updated the label's Adverse Reactions section to note that the signal was reviewed and not confirmed [5]. This conclusion was consistent with a NEJM Evidence analysis of over 100,000 patient records in the FDA Sentinel system.

Novo Nordisk's Patent Portfolio and Generic Competition

Novo Nordisk holds an extensive patent estate covering semaglutide. The core composition-of-matter patents, filed in the early 2000s, protect the specific fatty acid side-chain modification that gives semaglutide its 168-hour half-life. Multiple dosing and formulation patents extend protection into the 2030s.

Core Patent Timeline

The primary semaglutide composition patent (US 8,097,587) was granted in 2012 and is projected to expire in 2032. A cluster of secondary patents covering the once-weekly dosing regimen and the prefilled pen device (FlexTouch) extend potential exclusivity through approximately 2036. This means no FDA-approved generic injectable semaglutide is expected before 2033 at the earliest, barring successful inter partes review (IPR) petitions at the USPTO.

As of mid-2025, no generic manufacturer has filed an Abbreviated New Drug Application (ANDA) for injectable semaglutide that has been publicly docketed. The oral semaglutide formulation (Rybelsus) faces a separate but overlapping patent situation, with Hikma Pharmaceuticals filing a Paragraph IV certification in 2023 that triggered a 30-month litigation stay under Hatch-Waxman.

Hatch-Waxman Litigation for Oral Semaglutide

Novo Nordisk filed suit against Hikma in the District of New Jersey in late 2023, asserting infringement of patents covering the absorption-enhancing SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) carrier molecule. That case remains pending as of this writing. A ruling against Novo Nordisk could open oral semaglutide to generic competition as early as 2026, though analysts consider that outcome unlikely given the strength of the SNAC formulation patents.

The Compounding Controversy and FDA Shortage Litigation

The compounding dispute is the most commercially consequential legal battle currently surrounding semaglutide.

How the Shortage Started

The FDA added semaglutide to its drug shortage list in June 2022, citing manufacturing constraints at Novo Nordisk's fill-finish facilities. Once a drug appears on that list, Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act permit compounding pharmacies to prepare copies, even of patented molecules, without a specific patient prescription (for 503B outsourcing facilities). Hundreds of compounding pharmacies began producing semaglutide injections, often at lower price points than branded Ozempic or Wegovy.

FDA Removes Semaglutide from the Shortage List

In March 2024, the FDA announced that injectable semaglutide was no longer in shortage. That decision gave compounders a firm deadline to wind down production. The FDA stated that 503A pharmacies had until April 22, 2024 and 503B outsourcing facilities had until May 22, 2024 to stop compounding semaglutide.

Several large outsourcing facilities and trade associations filed for emergency injunctions in federal district court to block the FDA's enforcement timeline. The Outsourcing Facilities Association (OFA) sued in the Northern District of Texas, arguing the FDA's shortage determination was procedurally deficient and that the agency failed to adequately consider ongoing supply constraints [6]. As of July 2025, that litigation is ongoing with the court having denied the preliminary injunction in early 2025.

Novo Nordisk's Independent IP Claims Against Compounders

Separate from the FDA enforcement actions, Novo Nordisk filed civil complaints against multiple compounders alleging trademark infringement (use of "semaglutide" in ways that implied FDA-equivalent quality) and, in some cases, false advertising under the Lanham Act. These suits argue that compounders using unapproved salt forms of semaglutide (such as semaglutide acetate rather than the approved semaglutide base) were producing a materially different compound while marketing it as equivalent to Ozempic.

The FDA sent warning letters to at least six compounders between October 2023 and June 2024 specifically referencing the unapproved salt form issue, reinforcing Novo Nordisk's legal position [7].

The HealthRX medical team has developed a three-tier classification for how providers should evaluate compounded semaglutide products for patients:

Tier 1 (Acceptable, transitional use): Product compounded by an FDA-registered 503B outsourcing facility using semaglutide base (not acetate salt), with full Certificate of Analysis (CoA) from an ISO 17025-accredited lab, dispensed before the FDA's May 22, 2024 deadline.

Tier 2 (Requires individual physician judgment): Product from a 503A pharmacy, semaglutide base confirmed, CoA available, but dispensed after the FDA deadline. Prescriber must document clinical necessity and absence of commercial product availability.

Tier 3 (Do not prescribe): Any product using semaglutide acetate, sodium, or other non-approved salt forms; any product lacking a traceable CoA; any product from a facility not listed on the FDA's 503B outsourcing facility database.

Post-Market Safety Surveillance: What the Evidence Shows

The FDA's Sentinel System, which draws on claims data from more than 100 million insured Americans, has been the primary tool for post-market safety evaluation of semaglutide since 2018.

Thyroid Cancer Signal

The black-box thyroid warning has attracted ongoing post-market scrutiny. A 2023 analysis published in Diabetologia (N=145,410 patients with type 2 diabetes) found no statistically significant increase in thyroid cancer incidence among GLP-1 receptor agonist users compared with insulin users over a 7-year follow-up period [8]. The hazard ratio for thyroid cancer was 0.96 (95% CI 0.68 to 1.36), which did not meet the threshold for a new safety signal. That finding supports retaining the existing label warning without escalation.

Acute Pancreatitis

Acute pancreatitis remains a labeled warning for all GLP-1 receptor agonists. A 2024 BMJ meta-analysis of 14 randomized trials (N=90,360) found the absolute risk increase for acute pancreatitis with GLP-1 receptor agonists to be 0.13 per 100 patient-years, translating to a number needed to harm of approximately 769 over one year [9]. The FDA's current Ozempic label states that semaglutide "should be discontinued promptly" if pancreatitis is suspected and "should not be restarted" if confirmed.

Gallbladder Disease

Rapid weight loss associated with GLP-1 receptor agonist therapy accelerates cholesterol gallstone formation. SUSTAIN-6 reported cholelithiasis and cholecystitis at higher rates in the semaglutide arm (1.8%) versus placebo (1.2%) [2]. The 2022 label revision added cholelithiasis and cholecystitis to the Warnings and Precautions section, advising clinicians to evaluate patients who report biliary symptoms.

Gastroparesis and the Anesthesia Safety Signal

The gastroparesis signal overlaps with a separate anesthesia safety concern. The American Society of Anesthesiologists (ASA) issued guidance in 2023 recommending that GLP-1 receptor agonist users follow extended fasting protocols before elective procedures due to delayed gastric emptying and the associated aspiration risk [10]. The Ozempic label does not yet contain specific pre-procedural fasting language, though the 2022 GI motility update partially addresses the underlying mechanism.

Current Regulatory Status and What Prescribers Need to Know

As of July 2025, Ozempic retains FDA approval for type 2 diabetes at doses of 0.5 mg, 1.0 mg, and 2.0 mg. Off-label use for weight loss remains common but is not supported by the Ozempic label; Wegovy (semaglutide 2.4 mg) carries the obesity indication under NDA 213051.

Prescribing in the Context of Ongoing Litigation

The compounding litigation creates practical prescribing questions. Physicians writing prescriptions for compounded semaglutide after May 22, 2024 should document:

1. Why the FDA-approved product was not available or not accessible to the specific patient.
2. The specific compounding pharmacy's 503B registration status.
3. Confirmation that the product uses the approved semaglutide base.

Failure to document these points does not create automatic liability, but it weakens the prescriber's position if a patient experiences an adverse event and the product's equivalence to FDA-approved Ozempic is later contested.

Insurance and Prior Authorization Shifts

Multiple payers adjusted their prior authorization criteria between 2023 and 2025, directly responding to the patent and shortage litigation. UnitedHealthcare and CVS Caremark both moved semaglutide to higher formulary tiers in late 2024, citing increased utilization and the elimination of lower-cost compounded alternatives following the shortage delisting. Patients paying out of pocket for branded Ozempic currently face list prices of approximately $935 per month for the 2-pen package (4 doses), though Novo Nordisk's patient assistance programs cap costs at $99 per month for qualifying uninsured patients.

Key Regulatory Dates at a Glance

| Date | Event | |------|-------| | December 5, 2017 | FDA approves Ozempic (NDA 209637) for type 2 diabetes | | March 2020 | Label updated to include CV risk reduction indication | | June 2022 | FDA places injectable semaglutide on drug shortage list | | Late 2022 | Label updated for gastroparesis/GI motility warnings | | October 2023 | FDA begins warning letter campaign against compounders using semaglutide acetate | | March 2024 | FDA removes semaglutide from drug shortage list | | April-May 2024 | Compounding deadlines for 503A and 503B facilities | | Early 2025 | FDA/EMA conclude suicidality signal does not warrant new label warning |